NXTC: Rounding Bottom detected on 20 Oct 2026

NXTC is forming a rounding bottom with strong technical underpinnings: structure score 13.0/15, breakout score 13.0/13, and volume score 12.0/12 deliver an overall score of 71. The stock trades at $5.67, well below the 52-week high (down 63.98%) but significantly above the 52-week low (up 265.81%), establishing a solid recovery foundation. Key support sits at $1.55; key resistance at $10.93. The rounding bottom follows two prior bullish patterns—a bull flag (31.4 quality) and bullish pennant (30.0 quality)—both showing good strength, which reinforces the upside setup.

NextCure announced a merger with Avere Therapeutics on July 14, 2026, to advance a once-weekly oral IL-23 therapy. Upon closing expected in the second half of 2026, the combined company will operate as Avere Therapeutics and trade as "AVRX", with existing NXTC stockholders receiving CVRs tied to legacy assets. In June, NextCure presented positive SIM0505 Phase 1 dose escalation data for gynecologic cancers at ASCO 2026. The FDA granted Fast Track designation for SIM0505 in platinum-resistant ovarian cancer. Q2 2026 showed cash of $20.1M and a net loss of $14.9M. The merger catalyst and clinical progress explain the 10.96% gain over three months, though near-term volatility reflects transformation uncertainty.

A successful breakout from the rounding bottom projects to $6.02 conservatively (target_conservative field), with potential extension toward the $10.93 resistance zone. The 68.65% win_probability suggests solid historical breakout follow-through. Volume confirmation is essential—current volume of 67,235 shares runs 0.76x the 20-day average, indicating subdued participation; sustained volume >1.0x relative volume on the breakout would validate momentum. The pattern invalidates below key support at $1.55. ATR of 0.77 (13.58% annualized volatility) and beta of 1.86 signal elevated swings, so breakout confirmation should be pronounced.

Critical risks surround merger execution: NextCure faced court review of a reverse stock split in September 2026, signaling shareholder/regulatory friction that could delay or threaten the deal. Cash on hand is only $20.1M, creating a runway pressure that depends on merger close timing. The stock is down 14.61% in one week, and the broader market regime is bearish (regime_score -0.24), which conflicts with this stock's recovery narrative. Beta of 1.86 implies 86% higher volatility than the market, amplifying downside whipsaws in sector weakness. RSI at 45.87 is neutral but not overbought, so the risk is asymmetric if merger contingencies fail or SIM0505 trial results disappoint in H2 2026.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.